



## Board Communiqué

### The Board approves a VCU in the Zemplar matter

**OTTAWA, September 26, 2007:** The Patented Medicine Prices Review Board ("Board") approved a Voluntary Compliance Undertaking ("VCU") agreed to by Abbott Laboratories Limited and Board Staff to ensure that, among other things, the price of Zemplar IV is not excessive and to offset alleged excess revenues in the amount of \$58,741.67.

The Board issued a Notice of Hearing on July 24, 2007, pertaining to the allegations of Board Staff that Zemplar IV had been, and was being, sold by Abbott Laboratories at prices exceeding those indicated by the Board's Excessive Price Guidelines. On September 17, 2007, the Board received the above-mentioned VCU which proposed to resolve all issues raised by the Notice of Hearing.

By Order of the Board, the proceeding that was commenced by the issuance of Notice of Hearing on July 24, 2007 was concluded.

Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. It is a synthetic vitamin D analogue, paricalcitol.

The Board's Order is a public document and is available on the PMPRB Web site under Regulatory; Hearings; **Zemplar**, and under Voluntary Compliance Undertakings, or by contacting the Secretary of the Board.

---

Sylvie Dupont  
Secretary of the Patented Medicine Prices Review Board  
Toll-free #: 1 877 861-2350; Direct line: (613) 954-8299  
E-mail address: [sdupont@pmprb-cepmb.gc.ca](mailto:sdupont@pmprb-cepmb.gc.ca)